01011 泰凌醫藥
按盘价 
0.380 +0.015 (+4.110%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | -16.091% | -21.514% | -6.772% | -13.290% | -23.121% |
| 股东资金回报率 (%) | N/A | N/A | N/A | N/A | -588.461% |
| 资本运用回报率 (%) | N/A | N/A | N/A | -251.803% | -257.947% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | 13.857% | -- | 60.498% | 64.164% | 60.841% |
| 未计利息、税项、折旧及摊销前利润率 (%) | -83.064% | -548.276% | 14.236% | -23.161% | -41.581% |
| 税前边际利润率 (%) | -140.885% | -453.014% | -26.218% | -65.617% | -90.330% |
| 纯利率 (%) | -140.561% | -1949.362% | -32.065% | -65.963% | -161.276% |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 0.022 X | 0.018 X | 0.063 X | 0.299 X | 0.499 X |
| 速动比率 (X) | 0.022 X | 0.018 X | 0.054 X | 0.263 X | 0.475 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 219.467% | 203.173% | 124.028% | 122.125% | 98.269% |
| 总债项 / 总资产比率 (%) | 112.536% | 104.807% | 82.176% | 87.099% | 65.746% |
| 净债项 / 总资产比率 (%) | 109.655% | 104.345% | 81.586% | 86.111% | 65.152% |
| 总债项 / 股东资金比率 (%) | N/A | N/A | N/A | N/A | 5230.389% |
| 长期债项 / 股东资金比率 (%) | N/A | N/A | N/A | N/A | 319.743% |
| 净债项 / 股东资金比率 (%) | N/A | N/A | N/A | N/A | 5183.125% |
| 净现金 / (债项) ($) | (3.66亿) | (3.43亿) | (8.21亿) | (8.23亿) | (8.44亿) |
| 每股净现金 / (债项) ($) | (1.387) | (1.300) | (4.308) | (0.432) | (0.443) |
| 总债项 / 资本运用比率 (%) | N/A | N/A | N/A | 1401.165% | 614.179% |
| 利息盈利率 (X) | N/A | N/A | 0.243 X | N/A | N/A |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 1.875日 | N/A | 94.418日 | 133.195日 | 129.787日 |
| 应收贸易帐周转率日数 (日) | N/A | 1083.157日 | 40.642日 | 30.926日 | 73.701日 |
| 应付贸易帐周转率日数 (日) | 7.077日 | 234.158日 | 46.801日 | 73.521日 | 67.026日 |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -53,357,000 |
| 增长率 | -62.841% |
| 每股盈利/(亏损) | RMB -0.202 |
| 每股账面资产净值 (¥) | RMB -1.511 |